Safety and Efficacy of COVIDEX™ Therapy in Management of Adult COVID-19 Patients in Uganda.

Makerere University584 enrolled

Overview

The SARS-CoV-2 pandemic continues to grow, with over 350,000 new infections and over 7,000 daily global deaths in May 2021 (WHO, 2021a). The current supplies of protective vaccines are too low to cover the worldwide demand hence researchers globally are urgently looking for interventions to prevent new infections, prevent disease progression, and lessen disease severity for those already infected. According to data released by the ministry of health, Uganda had 94,904 confirmed cases with 2752 deaths at the end of July 2021 (MoH, 2021). Fortunately, most of the cases confirmed had a mild illness for whom home-based symptomatic management with monitoring of clinical deterioration as per World Health Organization recommendations is sufficing (WHO, 2021b). However, despite providing symptomatic management, a therapeutic drug that would limit infection is greatly needed to stop COVID-19 disease progression. While a number of claims on efficacy of herbal remedies on COVID-19 have been made, to our knowledge none of such claims have gained on scientific basis for continued use or further research and development of the constituents into investigational products. COVIDEX is a herbal formulation containing berberine as a primary anti-SARSCOV-2 compound notified by the Uganda National Drug Authority for supportive treatment in managing viral infections. Notably, this notification was done with a call for clinical trials to validate the claims of its anti-SARS COV-2 activity. This study therefore proposes to investigate the safety and efficacy of COVIDEXTm therapy in managing COVID-19 disease.

Study Type

INTERVENTIONAL

Allocation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Provision of signed/thumb printed and dated informed consent form 2. Willingness to comply with all study procedures and availability over the study duration 3. Patients aged 18years and above 4. Positive SARS-CoV-2 antigen rapid test and/or PCR positive for SARS-Cov-2 (COVID-19) 5. Symptomatic patients in the following categories; mild, moderate and severe: mild score 2 (limitation of activities), Moderately ill COVID-19 patients WHO score 3(Hospitalized with no oxygen therapy), which translates to moderately ill patients according to MOH Uganda, WHO Score 4 (Hospitalized with oxygen by mask or nasal prongs) and WHO score 5 (Non-invasive ventilation or high flow oxygen) which translates to severe COVID-19 disease on high flow oxygen patients according to the MOH Uganda COVID-19 disease category. Exclusion Criteria: 1. Patients who report use of COVIDEX with-in three days prior to presentation to the hospital. 2. Clinical diagnosis of severe renal (defined by GFR ≤ 29 mL/min/1.73 m2) and hepatic impairment (defined by \>2.5 times the upper normal value of ALT and AST). 3. Pregnancy or breast feeding. 4. Current use of remdesivir and molnupiravir therapy. 5. Active participation in another clinical trial or using another drug on compassionate use such as fluvoxamide. 6. Very ill patients with multiple comorbidities where determination of clinical outcome will be difficult as judged by the attending physician.

Outcomes

Primary Outcomes

Safety primary outcome

Incidence of severe adverse events of grade 3 and above Minimum score: 0, Maximum score: 4. The higher the score, the worse is the adverse event

Time frame: Daily for 30 days

Efficacy primary outcome:

Clinical recovery as measured by the WHO COVID ordinal improvement score Minimum score:0, Maximum score: 8. The higher the score, the worse is the clinical recovery

Time frame: Day 8

Secondary Outcomes

SARS-CoV-2 antigen present in the nasopharynx

Time frame: Day 8 and day 14

SARS-CoV-2 viral load in the nasopharynx as measured by the CT values